Increased melanoma risk in Parkinson disease

A prospective clinicopathological study

John M. Bertoni, John Philip Arlette, Hubert H. Fernandez, Cheryl Fitzer-Attas, Karen Frei, Mohamed N. Hassan, Stuart H. Isaacson, Mark F. Lew, Eric Molho, William G. Ondo, Tania J. Phillips, Carlos Singer, James P. Sutton, John E. Wolf

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objective: To evaluate the possible association of Parkinson disease (PD) and melanoma in North America. Design, Setting, and Patients: Thirty-one centers enrolled patients with idiopathic PD. At visit 1, a neurologist obtained a medical history. At visit 2, a dermatologist recorded melanoma risk factors, performed a whole-body examination, and performed a biopsy of lesions suggestive of melanoma for evaluation by a central dermatopathology laboratory. We compared overall prevalence of melanoma with prevalence calculated from the US Surveillance Epidemiology and End Results (SEER) cancer database and the American Academy of Dermatology skin cancer screening programs. Results: A total of 2106 patients (mean [SD] age, 68.6 [10.6] years; duration of PD, 7.1 [5.7] years) completed the study. Most (84.8%) had received levodopa. Dermatology examinations revealed 346 pigmented lesions; dermatopathological findings confirmed 20 in situ melanomas (0.9%) and 4 invasive melanomas (0.2%). In addition, histories revealed 68 prior melanomas (3.2%). Prevalence (5-year limited duration) of invasive malignant melanoma in the US cohort of patients with PD (n=1692) was 2.24-fold higher (95% confidence interval, 1.21-4.17) than expected in age- and sex-matched populations in the US SEER database. Age- or sex-adjusted relative risk of any melanoma for US patients was more than 7 times that expected from confirmed cases in American Academy of Dermatology skin cancer screening programs. Conclusions: Melanoma prevalence appears to be higher in patients with PD than in the general population. Despite difficulties in comparing other databases with this study population, the study supports increased melanoma screening in patients with PD.

Original languageEnglish
Pages (from-to)347-352
Number of pages6
JournalArchives of Neurology
Volume67
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Parkinson Disease
Melanoma
Prospective Studies
Skin Neoplasms
Databases
Early Detection of Cancer
Epidemiology
Parkinson's Disease
Population
Levodopa
North America
Dermatology
Confidence Intervals
Biopsy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Bertoni, J. M., Arlette, J. P., Fernandez, H. H., Fitzer-Attas, C., Frei, K., Hassan, M. N., ... Wolf, J. E. (2010). Increased melanoma risk in Parkinson disease: A prospective clinicopathological study. Archives of Neurology, 67(3), 347-352. https://doi.org/10.1001/archneurol.2010.1

Increased melanoma risk in Parkinson disease : A prospective clinicopathological study. / Bertoni, John M.; Arlette, John Philip; Fernandez, Hubert H.; Fitzer-Attas, Cheryl; Frei, Karen; Hassan, Mohamed N.; Isaacson, Stuart H.; Lew, Mark F.; Molho, Eric; Ondo, William G.; Phillips, Tania J.; Singer, Carlos; Sutton, James P.; Wolf, John E.

In: Archives of Neurology, Vol. 67, No. 3, 01.03.2010, p. 347-352.

Research output: Contribution to journalArticle

Bertoni, JM, Arlette, JP, Fernandez, HH, Fitzer-Attas, C, Frei, K, Hassan, MN, Isaacson, SH, Lew, MF, Molho, E, Ondo, WG, Phillips, TJ, Singer, C, Sutton, JP & Wolf, JE 2010, 'Increased melanoma risk in Parkinson disease: A prospective clinicopathological study', Archives of Neurology, vol. 67, no. 3, pp. 347-352. https://doi.org/10.1001/archneurol.2010.1
Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN et al. Increased melanoma risk in Parkinson disease: A prospective clinicopathological study. Archives of Neurology. 2010 Mar 1;67(3):347-352. https://doi.org/10.1001/archneurol.2010.1
Bertoni, John M. ; Arlette, John Philip ; Fernandez, Hubert H. ; Fitzer-Attas, Cheryl ; Frei, Karen ; Hassan, Mohamed N. ; Isaacson, Stuart H. ; Lew, Mark F. ; Molho, Eric ; Ondo, William G. ; Phillips, Tania J. ; Singer, Carlos ; Sutton, James P. ; Wolf, John E. / Increased melanoma risk in Parkinson disease : A prospective clinicopathological study. In: Archives of Neurology. 2010 ; Vol. 67, No. 3. pp. 347-352.
@article{8e8359e815fa4df6b0b777be64abf910,
title = "Increased melanoma risk in Parkinson disease: A prospective clinicopathological study",
abstract = "Objective: To evaluate the possible association of Parkinson disease (PD) and melanoma in North America. Design, Setting, and Patients: Thirty-one centers enrolled patients with idiopathic PD. At visit 1, a neurologist obtained a medical history. At visit 2, a dermatologist recorded melanoma risk factors, performed a whole-body examination, and performed a biopsy of lesions suggestive of melanoma for evaluation by a central dermatopathology laboratory. We compared overall prevalence of melanoma with prevalence calculated from the US Surveillance Epidemiology and End Results (SEER) cancer database and the American Academy of Dermatology skin cancer screening programs. Results: A total of 2106 patients (mean [SD] age, 68.6 [10.6] years; duration of PD, 7.1 [5.7] years) completed the study. Most (84.8{\%}) had received levodopa. Dermatology examinations revealed 346 pigmented lesions; dermatopathological findings confirmed 20 in situ melanomas (0.9{\%}) and 4 invasive melanomas (0.2{\%}). In addition, histories revealed 68 prior melanomas (3.2{\%}). Prevalence (5-year limited duration) of invasive malignant melanoma in the US cohort of patients with PD (n=1692) was 2.24-fold higher (95{\%} confidence interval, 1.21-4.17) than expected in age- and sex-matched populations in the US SEER database. Age- or sex-adjusted relative risk of any melanoma for US patients was more than 7 times that expected from confirmed cases in American Academy of Dermatology skin cancer screening programs. Conclusions: Melanoma prevalence appears to be higher in patients with PD than in the general population. Despite difficulties in comparing other databases with this study population, the study supports increased melanoma screening in patients with PD.",
author = "Bertoni, {John M.} and Arlette, {John Philip} and Fernandez, {Hubert H.} and Cheryl Fitzer-Attas and Karen Frei and Hassan, {Mohamed N.} and Isaacson, {Stuart H.} and Lew, {Mark F.} and Eric Molho and Ondo, {William G.} and Phillips, {Tania J.} and Carlos Singer and Sutton, {James P.} and Wolf, {John E.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1001/archneurol.2010.1",
language = "English",
volume = "67",
pages = "347--352",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Increased melanoma risk in Parkinson disease

T2 - A prospective clinicopathological study

AU - Bertoni, John M.

AU - Arlette, John Philip

AU - Fernandez, Hubert H.

AU - Fitzer-Attas, Cheryl

AU - Frei, Karen

AU - Hassan, Mohamed N.

AU - Isaacson, Stuart H.

AU - Lew, Mark F.

AU - Molho, Eric

AU - Ondo, William G.

AU - Phillips, Tania J.

AU - Singer, Carlos

AU - Sutton, James P.

AU - Wolf, John E.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Objective: To evaluate the possible association of Parkinson disease (PD) and melanoma in North America. Design, Setting, and Patients: Thirty-one centers enrolled patients with idiopathic PD. At visit 1, a neurologist obtained a medical history. At visit 2, a dermatologist recorded melanoma risk factors, performed a whole-body examination, and performed a biopsy of lesions suggestive of melanoma for evaluation by a central dermatopathology laboratory. We compared overall prevalence of melanoma with prevalence calculated from the US Surveillance Epidemiology and End Results (SEER) cancer database and the American Academy of Dermatology skin cancer screening programs. Results: A total of 2106 patients (mean [SD] age, 68.6 [10.6] years; duration of PD, 7.1 [5.7] years) completed the study. Most (84.8%) had received levodopa. Dermatology examinations revealed 346 pigmented lesions; dermatopathological findings confirmed 20 in situ melanomas (0.9%) and 4 invasive melanomas (0.2%). In addition, histories revealed 68 prior melanomas (3.2%). Prevalence (5-year limited duration) of invasive malignant melanoma in the US cohort of patients with PD (n=1692) was 2.24-fold higher (95% confidence interval, 1.21-4.17) than expected in age- and sex-matched populations in the US SEER database. Age- or sex-adjusted relative risk of any melanoma for US patients was more than 7 times that expected from confirmed cases in American Academy of Dermatology skin cancer screening programs. Conclusions: Melanoma prevalence appears to be higher in patients with PD than in the general population. Despite difficulties in comparing other databases with this study population, the study supports increased melanoma screening in patients with PD.

AB - Objective: To evaluate the possible association of Parkinson disease (PD) and melanoma in North America. Design, Setting, and Patients: Thirty-one centers enrolled patients with idiopathic PD. At visit 1, a neurologist obtained a medical history. At visit 2, a dermatologist recorded melanoma risk factors, performed a whole-body examination, and performed a biopsy of lesions suggestive of melanoma for evaluation by a central dermatopathology laboratory. We compared overall prevalence of melanoma with prevalence calculated from the US Surveillance Epidemiology and End Results (SEER) cancer database and the American Academy of Dermatology skin cancer screening programs. Results: A total of 2106 patients (mean [SD] age, 68.6 [10.6] years; duration of PD, 7.1 [5.7] years) completed the study. Most (84.8%) had received levodopa. Dermatology examinations revealed 346 pigmented lesions; dermatopathological findings confirmed 20 in situ melanomas (0.9%) and 4 invasive melanomas (0.2%). In addition, histories revealed 68 prior melanomas (3.2%). Prevalence (5-year limited duration) of invasive malignant melanoma in the US cohort of patients with PD (n=1692) was 2.24-fold higher (95% confidence interval, 1.21-4.17) than expected in age- and sex-matched populations in the US SEER database. Age- or sex-adjusted relative risk of any melanoma for US patients was more than 7 times that expected from confirmed cases in American Academy of Dermatology skin cancer screening programs. Conclusions: Melanoma prevalence appears to be higher in patients with PD than in the general population. Despite difficulties in comparing other databases with this study population, the study supports increased melanoma screening in patients with PD.

UR - http://www.scopus.com/inward/record.url?scp=77749330753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749330753&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.1

DO - 10.1001/archneurol.2010.1

M3 - Article

VL - 67

SP - 347

EP - 352

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 3

ER -